TY - JOUR
T1 - Pharmacogenetic approaches to hypertension therapy
T2 - Design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study
AU - Arnett, D. K.
AU - Boerwinkle, E.
AU - Davis, B. R.
AU - Eckfeldt, J.
AU - Ford, C. E.
AU - Black, H.
PY - 2002
Y1 - 2002
N2 - The Genetics of Hypertension Associated Treatment (GenHAT) study will determine whether variants in hypertension susceptibility genes interact with antihypertensive medication to modify coronary heart disease (CHD) risk in hypertensives. GenHAT is an ancillary study of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, ALLHAT, a double-blind, randomized trial of 42 418 hypertensives, 55 years of age or older, with systolic or diastolic hypertension and one or more risk factors for cardiovascular disease. About 50% are non-white, and about half are female. ALLHAT completes follow-up in March 2002. GenHAT is typing variants in hypertension genes; completion of genotyping is scheduled for 2003. Analysis of gene-treatment interactions in relation to outcomes include CHD, stroke, heart failure, and blood pressure lowering. To our knowledge, GenHAT is the largest pharmacogenetic study ever conducted. An added strength is its ability to link gene-treatment interactions with important clinical outcomes across diverse ethnic and gender groups.
AB - The Genetics of Hypertension Associated Treatment (GenHAT) study will determine whether variants in hypertension susceptibility genes interact with antihypertensive medication to modify coronary heart disease (CHD) risk in hypertensives. GenHAT is an ancillary study of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, ALLHAT, a double-blind, randomized trial of 42 418 hypertensives, 55 years of age or older, with systolic or diastolic hypertension and one or more risk factors for cardiovascular disease. About 50% are non-white, and about half are female. ALLHAT completes follow-up in March 2002. GenHAT is typing variants in hypertension genes; completion of genotyping is scheduled for 2003. Analysis of gene-treatment interactions in relation to outcomes include CHD, stroke, heart failure, and blood pressure lowering. To our knowledge, GenHAT is the largest pharmacogenetic study ever conducted. An added strength is its ability to link gene-treatment interactions with important clinical outcomes across diverse ethnic and gender groups.
KW - Amlodipine
KW - Chlorthalldone
KW - Doxazosin
KW - Hypertension
KW - Pharmacogenetics:Genetic polymorphism
UR - http://www.scopus.com/inward/record.url?scp=0036448441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036448441&partnerID=8YFLogxK
U2 - 10.1038/sj.tpj.6500113
DO - 10.1038/sj.tpj.6500113
M3 - Article
C2 - 12439737
AN - SCOPUS:0036448441
SN - 1470-269X
VL - 2
SP - 309
EP - 317
JO - Pharmacogenomics Journal
JF - Pharmacogenomics Journal
IS - 5
ER -